Correction: Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Thomas Otten; Rob Riemsma; Ben Wijnen; Nigel Armstrong; Lisa Stirk; Caroline Gordon; Bram Ramaekers; Jos Kleijnen; Manuela Joore; Sabine Grimm

doi:10.1007/s40273-023-01315-1

Correction: Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Thomas Otten^*
, Rob Riemsma
, Ben Wijnen
, Nigel Armstrong
, Lisa Stirk
, Caroline Gordon
, Bram Ramaekers
, Jos Kleijnen
, Manuela Joore
, Sabine Grimm

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum › Academic

Abstract

In the original PDF of this article, some part of the text in Section 2 was inadvertently omitted. The original article PDF has been corrected. The HTML version was unaffected.

Original language	English
Pages (from-to)	1551-1551
Number of pages	1
Journal	Pharmacoeconomics
Volume	41
Issue number	11
DOIs	https://doi.org/10.1007/s40273-023-01315-1
Publication status	Published - Nov 2023

Access to Document

10.1007/s40273-023-01315-1Licence: CC BY-NC

Issues in the inhalation toxicity testing and hazard assessment for low density particulate materials such as synthetic amorphous silica (SAS)
Dekant, W., Antoniou, E. E., Bosch, A., Bruer, G. G., Colnot, T., Creutzenberg, O., Drexel, C. P., Duffin, R., Krueger, N., Nolde, J., Poland, C., Schaudien, D., Schuster, T. B., Stintz, M., Weber, K., Wessely, B. & Zeegers, M. P., Aug 2024, In: Toxicology Letters. 399, p. 2-11 10 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Cite this

Otten, T., Riemsma, R., Wijnen, B., Armstrong, N., Stirk, L., Gordon, C., Ramaekers, B., Kleijnen, J., Joore, M., & Grimm, S. (2023). Correction: Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 41(11), 1551-1551. https://doi.org/10.1007/s40273-023-01315-1

@article{d6b1db34aae948f9a1350e46fadcde83,

title = "Correction: Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

abstract = "In the original PDF of this article, some part of the text in Section 2 was inadvertently omitted. The original article PDF has been corrected. The HTML version was unaffected.",

author = "Thomas Otten and Rob Riemsma and Ben Wijnen and Nigel Armstrong and Lisa Stirk and Caroline Gordon and Bram Ramaekers and Jos Kleijnen and Manuela Joore and Sabine Grimm",

year = "2023",

month = nov,

doi = "10.1007/s40273-023-01315-1",

language = "English",

volume = "41",

pages = "1551--1551",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis",

number = "11",

}

Otten, T, Riemsma, R, Wijnen, B, Armstrong, N, Stirk, L, Gordon, C, Ramaekers, B, Kleijnen, J, Joore, M & Grimm, S 2023, 'Correction: Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics, vol. 41, no. 11, pp. 1551-1551. https://doi.org/10.1007/s40273-023-01315-1

TY - JOUR

T1 - Correction: Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus

T2 - An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Otten, Thomas

AU - Riemsma, Rob

AU - Wijnen, Ben

AU - Armstrong, Nigel

AU - Stirk, Lisa

AU - Gordon, Caroline

AU - Ramaekers, Bram

AU - Kleijnen, Jos

AU - Joore, Manuela

AU - Grimm, Sabine

PY - 2023/11

Y1 - 2023/11

N2 - In the original PDF of this article, some part of the text in Section 2 was inadvertently omitted. The original article PDF has been corrected. The HTML version was unaffected.

AB - In the original PDF of this article, some part of the text in Section 2 was inadvertently omitted. The original article PDF has been corrected. The HTML version was unaffected.

U2 - 10.1007/s40273-023-01315-1

DO - 10.1007/s40273-023-01315-1

M3 - Erratum / corrigendum

SN - 1170-7690

VL - 41

SP - 1551

EP - 1551

JO - Pharmacoeconomics

JF - Pharmacoeconomics

IS - 11

ER -

Correction: Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Abstract

Access to Document

Fingerprint

Research output

Issues in the inhalation toxicity testing and hazard assessment for low density particulate materials such as synthetic amorphous silica (SAS)

Cite this